Semler Scientific (SMLR) shares fell 4.9% in recent Monday trading after the company disclosed in a regulatory filing last Friday that the US Department of Justice is investigating whether it violated the federal False Claims Act by marketing tests on devices that use photoplethysmography technology as reimbursable by Medicare.
The company said it began initial settlement discussions with the DOJ on Feb. 11 but ceased the talks on the same day.
"Accordingly, there is a risk that DOJ will file a complaint or complaint in intervention in a civil False Claims Act lawsuit seeking damages," Semler said in the filing. "We do not believe the amount of loss can be reasonably estimated."
Price: 40.82, Change: -2.10, Percent Change: -4.89
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.